The history of the erectile dysfunction drug presents a challenging picture for investors. While the initial introduction generated substantial returns, the end of its patent opened the avenue to generic competitors, https://socialstrategie.com/story7410770/the-copyright-and-the-pharmaceutical-industry-a-volatile-opportunity